title: Current strategies in the treatment of non-muscle-invasive bladder cancer.
abstract: This review is based on a data search up to the end of January 2012 on strategies in the treatment of non-muscle-invasive bladder cancer. One of the authors was chairman of the guidelines writing committee of the European Association of Urology, and these guidelines served as a backbone. They are updated and adapted according to the most recent data. It is astonishing how much important data were published in the last 2 years. Many data have a high level of evidence and allow well-supported recommendations. However, recommendations are not given but the discussion for reflection on it is given in this article.
authors.affiliation: Department of Urology, Ghent University Hospital, De Pintelaan, 185, 9000 Ghent, Belgium. willem.oosterlinck@ugent.be
authors.forename: Willem
authors.initials: W
authors.lastname: Oosterlinck
authors.forename: Karel
authors.initials: K
authors.lastname: Decaestecker
mesh_terms: D000283:Administration, Intravesical; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D001500:BCG Vaccine / Q000627:therapeutic use; D001706:Biopsy; D002278:Carcinoma in Situ / Q000601:surgery; D003558:Cystoscopy / Q000379:methods; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008297:Male; D009364:Neoplasm Recurrence, Local; D011184:Postoperative Period; D011467:Prostate / Q000473:pathology; D016896:Treatment Outcome; D014521:Urethra / Q000473:pathology; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis* / Q000188:drug therapy* / Q000601:surgery*
chemical_list: D000970:Antineoplastic Agents; D001500:BCG Vaccine